Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09UVF
|
|||
Drug Name |
Bicarboxylic and tricarboxylic ethynyl derivative 2
|
|||
Synonyms |
PMID28067079-Compound-25
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
H. LUNDBECK A/S
|
|||
Structure |
Download2D MOL |
|||
Formula |
C21H21N3O
|
|||
Canonical SMILES |
C1CC2(CCC(C1)(C2)NC(=O)C3=CC=CC=N3)C#CC4=CC=CC=N4
|
|||
InChI |
1S/C21H21N3O/c25-19(18-7-2-4-15-23-18)24-21-10-5-9-20(16-21,12-13-21)11-8-17-6-1-3-14-22-17/h1-4,6-7,14-15H,5,9-10,12-13,16H2,(H,24,25)/t20-,21+/m1/s1
|
|||
InChIKey |
ISUZZRVMDCKBEJ-RTWAWAEBSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator | [1] |
Target's Patent Info | Metabotropic glutamate receptor 5 (mGluR5) | Target's Patent Info | [1] | |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Long-term potentiation | ||||
Retrograde endocannabinoid signaling | ||||
Glutamatergic synapse | ||||
Huntington's disease | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
Metabotropic glutamate receptor group III pathway | ||||
Metabotropic glutamate receptor group I pathway | ||||
Endogenous cannabinoid signaling | ||||
Reactome | G alpha (q) signalling events | |||
Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
WikiPathways | Hypothetical Network for Drug Addiction | |||
GPCRs, Class C Metabotropic glutamate, pheromone | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.